Please ensure Javascript is enabled for purposes of website accessibility

Why Synergy Pharmaceuticals Shares Are Crashing 16% Today

By Todd Campbell – Mar 18, 2016 at 12:46PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A debt conversion is weighing on investors' minds.

IMAGE SOURCE: SYNERGY PHARMACEUTICALS.

What: After reporting that debt holders had converted their notes into shares at a significant discount to current share prices, shares in Synergy Pharmaceuticals, Inc.(NASDAQ: SGYP) are down 16.18% as of 11:30 a.m. ET today.

So what: The clinical-stage company filed for Food and Drug Administration approval of its first potential commercial drug on Jan. 29, and updated investors on its progress during its fourth-quarter conference call on Feb. 25.

The  FDA filing is for the approval of plecanatide, a treatment for chronic idiopathic constipation (CIC) that, if approved, will compete against Ironwood Pharmaceuticals' (IRWD 2.37%) Linzess, a drug that generated sales of $455 million last year.

Ongoing studies for the use of plecanatide in irritable bowel syndrome with constipation (IBS-C) should have results available this year, too, and if they're positive, the company plans to file for approval in that indication as well.

Plecanatide's progress is good news for the company, but investors should know that expenses have been soaring and, as a result, Synergy Pharmaceuticals lost $117.5 million last year, or $1.11 per share. Developing plecanatide has also resulted in its incurring significant liabilities in the form of senior convertible notes.

Today, Synergy Pharmaceuticals announced that some of those senior notes' holders will exchange $79.7 million worth of their debt for 33.3 million shares of the company's stock at an implied price of $2.47 per share.

Now what: The conversion significantly dilutes investors, but with a potential commercial launch upcoming and expenses taking a toll on its balance sheet, it's critical that the company right-sizes its liabilities. After this conversion, $71.5 million of these notes, which carry a 7.5% interest rate and were due in 2019, will be left remaining.

The conversion could prove to be good news for the company long term, but Synergy Pharmaceuticals' shares still have risks associated with them that ought to keep most investors at bay.

First, its spending in the past has resulted in a negative book value. Second, there's no guarantee that the FDA will green light plecanatide, or that if it does, it will win away market share from Ironwood. Finally, the company's spending pace is likely to remain high for the foreseeable future, and that means that there's no telling when it may turn profitable.

For all of those reasons, investors might be better off focusing on other high-growth opportunities, including this next one. 

Todd Campbell has no position in any stocks mentioned. Todd owns E.B. Capital Markets, LLC. E.B. Capital's clients may have positions in the companies mentioned. The Motley Fool has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Nearly 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Ironwood Pharmaceuticals Stock Quote
Ironwood Pharmaceuticals
IRWD
$12.11 (2.37%) $0.28

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
349%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/30/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.